<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anticardiolipin antibodies and the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> are strongly associated with <z:mp ids='MP_0005048'>thrombosis</z:mp> and appear to be the most common of the acquired blood protein defects causing <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the precise mechanism(s) whereby <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> alter hemostasis to induce a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> remain unclear, several theories have been advanced </plain></SENT>
<SENT sid="2" pm="."><plain>Because the aPTT is unreliable in patients with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and is not usually prolonged in patients with anticardiolipin antibodies, definitive tests, such as ELISA for IgG, IgA, and IgM anticardiolipin antibodies and the dRVVT (followed by cephalin correction for confirmation) for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, should be immediately ordered when suspecting <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> in persons with otherwise unexplained thrombotic or <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> or fetal wastage syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>The laboratory diagnosis of APL-T syndrome is summarized in Figure 1 </plain></SENT>
</text></document>